EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry

Souad Abdalla, Inger Westborg iD, Anni-Maria Pulkki-Brännström, Helena Norberg iD

Acta Ophthalmologica · 2025

DOI: 10.1111/aos.16774 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Souad Abdalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Translational Biology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Bevacizumab, Angiogenesis Inhibitors, Registries, Intravitreal Injections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umeå University, Umeå Universitet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To analyse the impact on cost if faricimab is used as the first‐line treatment for neovascular age‐related macular degeneration (nAMD) compared to standard treatment with bevacizumab.

Methods

Retrospective registry study including real‐world data from the Swedish Macula Registry between 2017 and 2022. The observed number of injections and visits for bevacizumab during the first two years of treatment was used ( n = 437 patients). Number of faricimab injections was obtained from published clinical trial data and unit costs mostly from publicly available Swedish sources. The provider cost included medication and visit cost and societal cost included additionally patient travel cost. Costs are presented in 2023 EUR.

Results

The incremental societal cost of faricimab was 277 EUR per patient compared to bevacizumab in the base case. Medication cost was higher (1516 EUR) while visit cost (−1183 EUR) and patient travel cost (−56 EUR) were lower due to longer injection intervals. Faricimab was of similar cost as bevacizumab for patients residing far from the clinic. The faricimab injection interval and the number of bevacizumab injections were major drivers of uncertainty in the results.

Conclusion

Faricimab represents a cost‐effective alternative to bevacizumab for patients with nAMD in Sweden. Its extended treatment interval is particularly beneficial for patients living far from clinics, and if the real‐life faricimab injection interval extends beyond 12 weeks. Our findings emphasize faricimab's potential to free up healthcare staff to treat a larger patient population with existing clinic resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabAngiogenesis InhibitorsRegistriesIntravitreal InjectionsWet Macular DegenerationCost-Benefit AnalysisVisual AcuityHumansSwedenRetrospective StudiesMaleFemaleAgedVascular Endothelial Growth Factor AMacula LuteaAged, 80 and overFollow-Up StudiesTomography, Optical CoherenceTreatment Outcome

Stichwörter der Autor:innen

AMDSwedish Macula Registrycost minimization analysisfaricimabreal‐world data

Substanzen

BevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Medical and Translational Biology, Umeå University, Umeå, Sweden.
  • Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden.
  • Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

ORCID-Profile: Inger Westborg, Helena Norberg

Förderung

  • Umeå University
  • Umeå Universitet

Zitieren

APA

Abdalla, S., Westborg, I., Pulkki-Brännström, A. M., & Norberg, H. (2025). Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry. Acta Ophthalmologica. https://doi.org/10.1111/aos.16774

Vancouver

Abdalla S, Westborg I, Pulkki-Brännström AM, Norberg H. Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry. Acta Ophthalmologica. 2025. doi:10.1111/aos.16774

BibTeX
@article{Abdalla2025,
  author = {Abdalla, Souad and Westborg, Inger and Pulkki-Brännström, Anni-Maria and Norberg, Helena},
  title = {Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry},
  journal = {Acta Ophthalmologica},
  year = {2025},
  doi = {10.1111/aos.16774}
}
Kostenlos starten →